When does the Goldline Pharmaceutical Limited IPO open and close?

The Goldline Pharmaceutical Limited IPO opens for subscription on May 12, 2026 and closes on May 14, 2026. According to the filing's indicative timetable, shares are expected to list on or about May 19, 2026.

What is the issue size of the Goldline Pharmaceutical Limited IPO?

The total issue size is ₹11.61 crore. This comprises a fresh issue of ₹11.61 crore, which the company receives, and an offer for sale of ₹0.00 crore, which goes to selling shareholders.

Who is the registrar for the Goldline Pharmaceutical Limited IPO?

The registrar to the issue is Cumulative Capital Private Limited.

Bidding ClosedMAINBOARDOfficial SEBI Filing

Goldline Pharmaceutical Limited

Price Band

—

Total Issue Size

₹11.61 Cr

Bidding Window

12 May – 14 May 2026

Market Lot

—

Subscription

—

Issue Timeline & Lifecycle

Issue Opens

12 May 2026

Issue Closes

14 May 2026

5

Allotment

15 May 2026

Indicative, per filing

6

Exchange Debut

19 May 2026

Indicative, per filing

Issue Opens

12 May 2026

Issue Closes

14 May 2026

5

Allotment

15 May 2026 · indicative

6

Exchange Debut

19 May 2026 · indicative

AI Company Profile

AI Snapshot

Goldline Pharmaceutical Limited distributes pharmaceutical products through a well-developed network. It earns revenue from product sales, focusing on operational efficiency and product portfolio expansion. Issue size ₹11.61 cr.

HQ:N.A

What Looks Strong

ProspectusMaintains cordial relations with various suppliers.
ProspectusProvides specified quantities at competitive rates to customers.

What to Watch

Risk factorReliance on a limited number of distributors for a large percentage of revenue.
Risk factorInability to expand sales to existing distributors could impact revenue.

Fundamentals & Key Metrics

Period:FY25

Profitability & Returns

5 items

EBITDA Marginℹ

20.78%

Profit Marginℹ

10.09%

RoNWℹ

27.37%

Basic EPSℹ

₹4.10

Book Valueℹ

₹12.38

Financial Health & Solvency

2 items

Total Debtℹ

₹11.03 Cr

Operating Cash Flowℹ

₹2.32 Cr

Financials at a glance

Restated Unspecified

Statement: Income StatementPeriod: Restated Multi-Year (FY)

Shareholding, Ownership & Dilution

6 disclosed holders

Pre-Offer Shareholding Distribution

Breakdown of major disclosed shareholders prior to the issue

100.00% Pre-Issue

100%Pre-Offer

Amol Laxmikant Mujumdar

39.85%

Swapan Premprakash Khandelwal

39.85%

Sumit Bilgaiyan

9.78%

Priya Chnadrakant Jalgaonkar

3.26%

SGMP Management Consultancy Private Limited

2.75%

Others

4.51%

Ownership Impact of the IPO

What is newly issued, what changes hands, and what stays put

The capital base is disclosed, but the offer is not priced and no complete offered-share count is available yet. A percentage would be speculative at this stage.

Disclosed Pre-Offer Shareholders Table

6

AI Summary

Filing-backed

Prospectus Research

Analyze business model, competitive strengths, use of issue proceeds, and disclosed risk factors with official page citations.

Issue intermediaries

Registrar to the issue

Cumulative Capital Private Limited

Listing venues

BSE

Listed Peer Valuation & Returns

Industry Avg P/E:18.26x

Swipe left / right to view all valuation metrics→

Company
Goldline Pharmaceutical LimitedThis Issue	10.49x	₹28.06 Cr	₹4.10	₹12.38	27.37%
Mono Pharmacare Limited	7.57x	₹168.34 Cr	₹1.75	₹17.66	9.90%
Chandra Bhagat Pharma Limited	28.94x	₹86.72 Cr	₹1.14	₹39.72	2.86%

Official Prospectus Filings

Goldline Pharmaceutical Limited

Type: RHP · Published: 2026-06-11

Goldline Pharmaceutical Limited

Issue Timeline & Lifecycle

What Looks Strong

What to Watch

Profitability & Returns

Financial Health & Solvency

Disclosed Pre-Offer Shareholders Table

AI Summary

Prospectus Research

Issue intermediaries

Listed Peer Valuation & Returns

Official Prospectus Filings

Frequently Asked Questions